broad_id
string | depmap_id
string | ccle_name
string | screen_id
string | upper_limit
int64 | lower_limit
float64 | slope
float64 | r2
float64 | auc
float64 | ec50
float64 | ic50
float64 | name
string | moa
string | target
string | disease.area
string | indication
string | smiles
string | phase
string | passed_str_profiling
bool | row_name
string |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BRD-K03449891-001-08-6 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.418406 | 0.330792 | 0.04628 | 1 | 0.000187 | null | foretinib | VEGFR inhibitor | FLT1, FLT4, KDR, MET | null | null | COc1cc2c(Oc3ccc(NC(=O)C4(CC4)C(=O)Nc4ccc(F)cc4)cc3F)ccnc2cc1OCCCN1CCOCC1 | Phase 2 | true | ACH-000970 |
BRD-K03765900-001-01-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.370081 | 0.340684 | -0.29675 | 1 | 0.041974 | null | XL-647 | EGFR inhibitor, VEGFR inhibitor | EGFR, EPHB4, ERBB2, FLT4, KDR | null | null | COc1cc2c(Nc3ccc(Cl)c(Cl)c3F)ncnc2cc1OC[C@H]1C[C@H]2CN(C)C[C@H]2C1 | Phase 3 | true | ACH-000970 |
BRD-K05804044-001-18-5 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.412424 | 1.19325 | 0.497532 | 0.666135 | 0.040109 | 0.172701 | AZ-628 | RAF inhibitor | BRAF, RAF1 | null | null | Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1, Cc1ccc(NC(=O)c2cccc(c2)C(C)(C)C#N)cc1Nc1ccc2ncn(C)c(=O)c2c1 | Preclinical | true | ACH-000970 |
BRD-K06814349-304-02-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.001462 | -0.855192 | -0.052049 | 1 | 0.010513 | null | fosbretabulin | tubulin polymerization inhibitor, VE-cadherin antagonist | CDH5 | null | null | COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(cc1OP(O)(O)=O)\C=C/c1cc(OC)c(OC)c(OC)c1, COc1ccc(C=Cc2cc(OC)c(OC)c(OC)c2)cc1OP(O)(O)=O | Phase 3 | true | ACH-000970 |
BRD-K08109215-001-06-4 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.204606 | 0.278089 | -0.063608 | 1 | 0.030459 | null | I-BET-762 | bromodomain inhibitor | BRD2, BRD3, BRD4 | null | null | CCNC(=O)C[C@@H]1N=C(c2ccc(Cl)cc2)c2cc(OC)ccc2-n2c(C)nnc12 | Phase 2 | true | ACH-000970 |
BRD-K08542803-001-02-3 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.221912 | 0.276495 | 0.230619 | 0.644713 | 0.160559 | 1.340048 | gambogic-acid | caspase activator | BCL2 | null | null | CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C, CC(C)=CCC[C@@]1(C)Oc2c(CC=C(C)C)c3O[C@@]45[C@H]6C[C@@H](C=C4C(=O)c3c(O)c2C=C1)C(=O)[C@]5(C\C=C(\C)C(O)=O)OC6(C)C | Phase 2 | true | ACH-000970 |
BRD-K08547377-001-04-4 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 2.697791 | 0.400362 | 0.327244 | 1 | 1.102052 | null | irinotecan | topoisomerase inhibitor | TOP1, TOP1MT | oncology | colorectal cancer | CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12, CCc1c2Cn3c(cc4c(COC(=O)[C@]4(O)CC)c3=O)-c2nc2ccc(OC(=O)N3CCC(CC3)N3CCCCC3)cc12 | Launched | true | ACH-000970 |
BRD-K08703257-001-13-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.113753 | 0.045662 | -0.034739 | 1 | 0.009427 | null | 3-amino-benzamide | PARP inhibitor | PARP1 | null | null | NC(=O)c1cccc(N)c1, NC(=O)c1cccc(N)c1 | Phase 2 | true | ACH-000970 |
BRD-K09951645-001-11-8 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.578975 | 6.296121 | 0.607309 | 0.639076 | 0.002438 | null | dabrafenib | RAF inhibitor | BRAF, LIMK1, NEK11, RAF1, SIK1 | oncology | melanoma | CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F, CC(C)(C)c1nc(c(s1)-c1ccnc(N)n1)-c1cccc(NS(=O)(=O)c2c(F)cccc2F)c1F | Launched | true | ACH-000970 |
BRD-K11267252-001-05-1 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.343609 | 6.609385 | 0.156444 | 1 | 1.884103 | null | alectinib | ALK tyrosine kinase receptor inhibitor | ALK, MET | oncology | non-small cell lung cancer (NSCLC) | CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1, CCc1cc2C(=O)c3c([nH]c4cc(ccc34)C#N)C(C)(C)c2cc1N1CCC(CC1)N1CCOCC1 | Launched | true | ACH-000970 |
BRD-K11630072-001-13-2 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.380951 | 2.357641 | 0.188024 | 1 | 0.307898 | null | carmofur | thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O, CCCCCCNC(=O)n1cc(F)c(=O)[nH]c1=O | Launched | true | ACH-000970 |
BRD-K12184916-001-19-6 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.974049 | 1.168329 | 0.159994 | 1 | 0.01058 | null | NVP-BEZ235 | mTOR inhibitor, PI3K inhibitor | ATR, MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1, Cn1c2cnc3ccc(cc3c2n(-c2ccc(cc2)C(C)(C)C#N)c1=O)-c1cnc2ccccc2c1 | Phase 2 | true | ACH-000970 |
BRD-K12343256-001-14-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.374461 | 1.042583 | 0.355143 | 0.464529 | 0.001913 | 0.007202 | trametinib | MEK inhibitor | MAP2K1, MAP2K2 | oncology | melanoma | CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O, CC(=O)Nc1cccc(c1)-n1c2c(C)c(=O)n(C)c(Nc3ccc(I)cc3F)c2c(=O)n(C2CC2)c1=O | Launched | true | ACH-000970 |
BRD-K13049116-001-04-0 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.341449 | -1.104123 | 0.067232 | 0.92472 | 0.00135 | null | BMS-754807 | IGF-1 inhibitor | AKT1, IGF1R | null | null | C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1, C[C@]1(CCCN1c1nc(Nc2cc(n[nH]2)C2CC2)c2cccn2n1)C(=O)Nc1ccc(F)nc1 | Phase 2 | true | ACH-000970 |
BRD-K13390322-001-06-3 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.50053 | 3.548537 | 0.120452 | 0.916254 | 1.96658 | null | AT-7519 | CDK inhibitor | CDK1, CDK2, CDK4, CDK5, CDK6, CDK9 | null | null | Clc1cccc(Cl)c1C(=O)Nc1c[nH]nc1C(=O)NC1CCNCC1 | Phase 2 | true | ACH-000970 |
BRD-K13514097-001-04-6 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 2.475136 | 0.064948 | 0.080521 | 1 | 0.583149 | null | everolimus | mTOR inhibitor | MTOR | oncology, neurology/psychiatry, genetics, urology | breast cancer, neuroendocrine tumors of pancreatic origin (PNET), renal cell carcinoma (RCC), subependymal giant cell astrocytoma (SEGA), tuberous sclerosis complex (TSC), renal angiomyolipoma | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO, CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@H]1OCCO | Launched | true | ACH-000970 |
BRD-K13662825-001-07-5 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.263749 | 3.911679 | 0.682907 | 0.760007 | 0.105819 | 0.128175 | dinaciclib | CDK inhibitor | CDK1, CDK2, CDK5, CDK9 | null | null | CCc1cnn2c(NCc3ccc[n+]([O-])c3)cc(nc12)N1CCCC[C@H]1CCO | Phase 3 | true | ACH-000970 |
BRD-K14109347-001-03-4 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.659729 | 0.847405 | 0.292119 | 1 | 0.079542 | null | LY2603618 | CHK inhibitor | CHEK1 | null | null | Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1, Cc1cnc(NC(=O)Nc2cc(Br)c(C)cc2OC[C@@H]2CNCCO2)cn1 | Phase 2 | true | ACH-000970 |
BRD-K15179879-001-03-2 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.098565 | 0.338469 | 0.351568 | 0.483151 | 0.027065 | 0.051776 | carfilzomib | proteasome inhibitor | PSMA1, PSMA2, PSMA3, PSMA4, PSMA5, PSMA6, PSMA7, PSMA8, PSMB1, PSMB10, PSMB11, PSMB2, PSMB3, PSMB4, PSMB5, PSMB6, PSMB7, PSMB8, PSMB9 | hematologic malignancy | multiple myeloma | CC(C)C[C@H](NC(=O)[C@H](CCc1ccccc1)NC(=O)CN1CCOCC1)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(C)C)C(=O)[C@@]1(C)CO1 | Launched | true | ACH-000970 |
BRD-K15600710-066-05-8 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.180611 | -1.664109 | -0.030067 | 1 | 0.005863 | null | obatoclax | BCL inhibitor | BCL2 | null | null | COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1, COC1=CC(=N\C\1=C/c1[nH]c(C)cc1C)c1cc2ccccc2[nH]1 | Phase 3 | true | ACH-000970 |
BRD-K16730910-001-10-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.525005 | 0.128409 | -0.136765 | 0.73082 | 0.009034 | null | regorafenib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | ABL1, BRAF, DDR2, EPHA2, FGFR1, FGFR2, FLT1, FLT4, FRK, KDR, KIT, MAPK11, NTRK1, PDGFRA, PDGFRB, RAF1, RET, TEK | oncology | colorectal cancer, gastrointestinal stromal tumors (GIST) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)c(F)c2)ccn1 | Launched | true | ACH-000970 |
BRD-K17555800-003-02-3 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.975191 | 3.430524 | -0.273937 | 0.991301 | 0.332832 | null | talmapimod | p38 MAPK inhibitor | MAPK11, MAPK14 | null | null | C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C, C[C@H]1CN([C@H](C)CN1Cc1ccc(F)cc1)C(=O)c1cc2c(cn(C)c2cc1Cl)C(=O)C(=O)N(C)C | Phase 2 | true | ACH-000970 |
BRD-K17610631-001-03-3 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.64204 | 0.152372 | 0.052331 | 1 | 5.978035 | null | indisulam | CDK inhibitor | CA1, CA12, CA14, CA2, CA6, CA7, CA9 | null | null | NS(=O)(=O)c1ccc(cc1)S(=O)(=O)Nc1cccc2c(Cl)c[nH]c12 | Phase 2 | true | ACH-000970 |
BRD-K17894950-001-14-3 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.808321 | 5.724787 | -0.050424 | 0.929486 | 0.281535 | null | indirubin | CDK inhibitor, glycogen synthase kinase inhibitor | CDK1, CDK5, GSK3A | null | null | O=C1Nc2ccccc2\C1=C1\Nc2ccccc2C1=O | Phase 2/Phase 3 | true | ACH-000970 |
BRD-K18961567-001-01-1 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.456861 | 1.050004 | 0.176537 | 1 | 1.752722 | null | LY2801653 | MET inhibitor | MET | null | null | Cc1ccc(C(=O)Nc2ccc(Oc3cc4cnn(C)c4cc3-c3cn[nH]c3)c(F)c2)c(=O)n1-c1ccc(F)cc1 | Phase 2 | true | ACH-000970 |
BRD-K19540840-001-09-4 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.999493 | -0.291123 | -0.003076 | 0.999721 | 0.174811 | null | saracatinib | src inhibitor | ABL1, LCK, SRC, YES1 | null | null | CN1CCN(CCOc2cc(OC3CCOCC3)c3c(Nc4c5OCOc5ccc4Cl)ncnc3c2)CC1 | Phase 2/Phase 3 | true | ACH-000970 |
BRD-K19687926-001-04-1 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.483988 | 0.296112 | 0.135339 | 1 | 0.448063 | null | lapatinib | EGFR inhibitor | EGFR, ERBB2 | oncology | breast cancer | CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1, CS(=O)(=O)CCNCc1ccc(o1)-c1ccc2ncnc(Nc3ccc(OCc4cccc(F)c4)c(Cl)c3)c2c1 | Launched | true | ACH-000970 |
BRD-K22064724-001-01-8 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.186342 | 4.892547 | 0.438504 | 0.907666 | 3.327563 | 3.660315 | napabucasin | STAT inhibitor | STAT3 | null | null | CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O, CC(=O)c1cc2c(o1)C(=O)c1ccccc1C2=O | Phase 3 | true | ACH-000970 |
BRD-K22822991-001-02-3 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.922129 | 7.165008 | -0.039792 | 0.938799 | 0.004871 | null | odanacatib | cathepsin inhibitor | CTSK | null | null | CC(C)(F)C[C@H](N[C@@H](c1ccc(cc1)-c1ccc(cc1)S(C)(=O)=O)C(F)(F)F)C(=O)NC1(CC1)C#N | Phase 3 | true | ACH-000970 |
BRD-K23228615-001-02-8 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.29407 | 3.404373 | -0.034581 | 1 | 0.517605 | null | GDC-0980 | mTOR inhibitor, PI3K inhibitor | FGR, MAP3K9, MTOR, PIK3CA, PIK3CB, PIK3CD, PIK3CG, SYK | null | null | C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1, C[C@H](O)C(=O)N1CCN(Cc2sc3c(nc(nc3c2C)-c2cnc(N)nc2)N2CCOCC2)CC1 | Phase 2 | true | ACH-000970 |
BRD-K23984367-001-07-5 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.423989 | 0.296005 | -0.002819 | 1 | 0.116045 | null | sorafenib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RAF inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | BRAF, DDR2, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRB, RAF1, RET | oncology | renal cell carcinoma (RCC), thyroid cancer, hepatocellular carcinoma (HCC) | CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1, CNC(=O)c1cc(Oc2ccc(NC(=O)Nc3ccc(Cl)c(c3)C(F)(F)F)cc2)ccn1 | Launched | true | ACH-000970 |
BRD-K26657438-001-15-2 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.920284 | 1.39418 | 0.042893 | 0.967951 | 0.202658 | null | imiquimod | interferon inducer, toll-like receptor agonist | TLR7, TLR8 | dermatology, infectious disease, oncology | actinic keratosis (AK), genital warts, basal cell carcinoma (BCC) | CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12, CC(C)Cn1cnc2c(N)nc3ccccc3c12 | Launched | true | ACH-000970 |
BRD-K28822270-001-03-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.257301 | 0.059796 | -0.001968 | 1 | 0.05281 | null | resminostat | HDAC inhibitor | HDAC1, HDAC3, HDAC6, HDAC8 | null | null | CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO, CN(C)Cc1ccc(cc1)S(=O)(=O)n1ccc(c1)\C=C\C(=O)NO | Phase 2 | true | ACH-000970 |
BRD-K29905972-001-06-3 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.233784 | -3.394982 | -0.07371 | 1 | 21.78902 | null | axitinib | PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1, FLT1, FLT4, KDR, PLK4 | oncology | renal cell carcinoma (RCC) | CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1, CNC(=O)c1ccccc1Sc1ccc2c(\C=C\c3ccccn3)n[nH]c2c1 | Launched | true | ACH-000970 |
BRD-K30577245-001-05-0 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.13983 | 0.16985 | -0.024356 | 1 | 0.000144 | null | docetaxel | tubulin polymerization inhibitor | BCL2, MAP2, MAP4, MAPT, NR1I2, TUBB, TUBB1 | oncology | breast cancer, non-small cell lung cancer (NSCLC), prostate cancer, gastric adenocarcinoma, head and neck squamous cell carcinoma (HNSCC) | CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C, CC(=O)O[C@@]12CO[C@@H]1C[C@H](O)[C@]1(C)[C@@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)c3ccccc3)C(C)=C([C@@H](O)C1=O)C2(C)C | Launched | true | ACH-000970 |
BRD-K31698212-001-02-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.883093 | 0.107856 | -0.011165 | 0.934172 | 0.007048 | null | icotinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | C#Cc1cccc(Nc2ncnc3cc4OCCOCCOCCOc4cc23)c1 | Launched | true | ACH-000970 |
BRD-K31928526-001-02-1 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.749668 | 2.220498 | 0.412912 | 1 | 0.260707 | null | barasertib | Aurora kinase inhibitor | AURKA, AURKB | null | null | CCN(CCCOc1ccc2c(Nc3cc(CC(=O)Nc4cccc(F)c4)[nH]n3)ncnc2c1)CCOP(O)(O)=O | Phase 2/Phase 3 | true | ACH-000970 |
BRD-K33379087-001-07-5 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.086582 | 0.179264 | -0.005174 | 1 | 0.000063 | null | tivantinib | tyrosine kinase inhibitor | MET | null | null | O=C1NC(=O)[C@H]([C@@H]1c1c[nH]c2ccccc12)c1cn2CCCc3cccc1c23 | Phase 3 | true | ACH-000970 |
BRD-K33610132-001-02-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.831443 | -79.863133 | -0.340852 | 0.89835 | 0.212337 | null | rociletinib | EGFR inhibitor | EGFR | null | null | COc1cc(ccc1Nc1ncc(c(Nc2cccc(NC(=O)C=C)c2)n1)C(F)(F)F)N1CCN(CC1)C(C)=O | Phase 3 | true | ACH-000970 |
BRD-K33622447-066-01-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.354245 | 2.795919 | 0.338799 | 1 | 0.051193 | null | abemaciclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CCN1CCN(Cc2ccc(Nc3ncc(F)c(n3)-c3cc(F)c4nc(C)n(C(C)C)c4c3)nc2)CC1 | Launched | true | ACH-000970 |
BRD-K35520305-001-16-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.741463 | -0.37192 | -0.111326 | 0.895516 | 0.02109 | null | dacarbazine | DNA alkylating agent | PGD, POLA2 | oncology, hematologic malignancy | melanoma, Hodgkin's lymphoma | CN(C)\N=N\c1[nH]cnc1C(N)=O, CN(C)\N=N\c1[nH]cnc1C(N)=O | Launched | true | ACH-000970 |
BRD-K36627727-001-05-4 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.922053 | 1.292499 | 0.054136 | 0.947882 | 0.015022 | null | tamibarotene | retinoid receptor agonist | RARA, RARB | hematologic malignancy | acute promyelocytic leukemia (APL) | CC1(C)CCC(C)(C)c2cc(NC(=O)c3ccc(cc3)C(O)=O)ccc12 | Launched | true | ACH-000970 |
BRD-K36788280-001-01-2 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.265797 | -1.779803 | 0.14201 | 0.939261 | 0.001167 | 0.000762 | ribociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1, CN(C)C(=O)c1cc2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n1C1CCCC1 | Launched | true | ACH-000970 |
BRD-K37379014-001-02-0 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.962793 | -0.294945 | -0.061435 | 0.976132 | 0.012019 | null | filanesib | kinesin inhibitor, kinesin-like spindle protein inhibitor | KIF11 | null | null | CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F, CON(C)C(=O)N1N=C(S[C@@]1(CCCN)c1ccccc1)c1cc(F)ccc1F | Phase 3 | true | ACH-000970 |
BRD-K38332599-001-01-3 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.931655 | 0.61965 | -0.152967 | 0.981048 | 0.930565 | null | uprosertib | AKT inhibitor | AKT1, AKT2, AKT3 | null | null | Cn1ncc(Cl)c1-c1cc(oc1Cl)C(=O)N[C@H](CN)Cc1ccc(F)c(F)c1 | Phase 2 | true | ACH-000970 |
BRD-K38527262-300-01-0 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.284965 | 0.71133 | 0.556482 | 0.778043 | 0.533053 | 1.745578 | atiprimod | JAK inhibitor, STAT inhibitor | JAK2, STAT3 | null | null | CCCC1(CCC)CCC2(CCN(CCCN(CC)CC)C2)CC1 | Phase 2 | true | ACH-000970 |
BRD-K38852836-001-02-1 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.7547 | -1.802528 | -0.021635 | 0.989636 | 0.000161 | null | ganetespib | HSP inhibitor | HSP90AA1 | null | null | CC(C)c1cc(-c2n[nH]c(=O)n2-c2ccc3n(C)ccc3c2)c(O)cc1O | Phase 3 | true | ACH-000970 |
BRD-K39974922-001-04-3 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.842241 | -9.210229 | 0.299034 | 0.89877 | 0.308868 | null | lenvatinib | FGFR inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | FLT4, KDR | oncology | thyroid cancer | COc1cc2nccc(Oc3ccc(NC(=O)NC4CC4)c(Cl)c3)c2cc1C(N)=O | Launched | true | ACH-000970 |
BRD-K41859756-001-06-8 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 2.396653 | 0.364605 | 0.229148 | 1 | 0.318452 | null | NVP-AUY922 | HSP inhibitor | HSP90AA1, HSP90AB1 | null | null | CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O, CCNC(=O)c1noc(c1-c1ccc(CN2CCOCC2)cc1)-c1cc(C(C)C)c(O)cc1O | Phase 2 | true | ACH-000970 |
BRD-K42495768-001-01-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.33554 | 1.303565 | 0.22982 | 1 | 2.056865 | null | tasisulam | apoptosis stimulant | null | null | null | Clc1ccc(C(=O)NS(=O)(=O)c2ccc(Br)s2)c(Cl)c1 | Phase 3 | true | ACH-000970 |
BRD-K42805893-001-04-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.104037 | 0.068922 | -0.007249 | 1 | 0.004282 | null | osimertinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(N(C)CCN(C)C)c(NC(=O)C=C)cc1Nc1nccc(n1)-c1cn(C)c2ccccc12 | Launched | true | ACH-000970 |
BRD-K42828737-001-03-3 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.807704 | 1.056033 | -0.049748 | 0.918272 | 0.074105 | null | sunitinib | FLT3 inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, RET tyrosine kinase inhibitor, VEGFR inhibitor | CSF1R, FGFR1, FLT1, FLT3, FLT4, KDR, KIT, PDGFRA, PDGFRB, RET | oncology | gastrointestinal stromal tumors (GIST), renal cell carcinoma (RCC), neuroendocrine tumors of pancreatic origin (PNET) | CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C, CCN(CC)CCNC(=O)c1c(C)[nH]c(\C=C2/C(=O)Nc3ccc(F)cc23)c1C | Launched | true | ACH-000970 |
BRD-K42898655-001-01-8 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 2.757185 | 0.456506 | 0.630465 | 1 | 0.015085 | null | temsirolimus | mTOR inhibitor | MTOR | oncology | renal cell carcinoma (RCC) | CO[C@@H]1C[C@H](C[C@@H](C)[C@@H]2CC(=O)[C@H](C)\C=C(C)\[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)\C=C\C=C\C=C(C)\[C@H](C[C@H]3CC[C@@H](C)[C@@](O)(O3)C(=O)C(=O)N3CCCC[C@H]3C(=O)O2)OC)CC[C@@H]1OC(=O)C(C)(CO)CO | Launched | true | ACH-000970 |
BRD-K43389675-001-02-1 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.343387 | 0.866456 | -0.080265 | 1 | 0.001139 | null | daunorubicin | RNA synthesis inhibitor, topoisomerase inhibitor | TOP2A, TOP2B | hematologic malignancy | acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) | COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O, COc1cccc2C(=O)c3c(O)c4C[C@](O)(C[C@H](O[C@H]5C[C@H](N)[C@H](O)[C@H](C)O5)c4c(O)c3C(=O)c12)C(C)=O | Launched | true | ACH-000970 |
BRD-K44227013-001-06-4 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.413354 | 0.96779 | 0.423498 | 0.829521 | 0.638169 | 3.903874 | ponatinib | Bcr-Abl kinase inhibitor, FLT3 inhibitor, PDGFR tyrosine kinase receptor inhibitor | ABL1, BCR, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, KDR, KIT, LCK, LYN, PDGFRA, RET, SRC, TEK | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1, CN1CCN(Cc2ccc(NC(=O)c3ccc(C)c(c3)C#Cc3cnc4cccnn34)cc2C(F)(F)F)CC1 | Launched | true | ACH-000970 |
BRD-K44408410-001-17-6 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.156608 | 0.104609 | -0.018164 | 1 | 0.179327 | null | 2-methoxyestradiol | hypoxia inducible factor inhibitor | COMT, CYP19A1, CYP1A1, CYP1B1, HIF1A, TUBB | null | null | COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O, COc1cc2[C@H]3CC[C@]4(C)[C@@H](O)CC[C@H]4[C@@H]3CCc2cc1O | Phase 2 | true | ACH-000970 |
BRD-K44827188-001-06-0 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.582448 | -0.287724 | 0.068597 | 0.876996 | 0.002401 | null | vismodegib | hedgehog pathway inhibitor, smoothened receptor antagonist | SMO | oncology | basal cell carcinoma (BCC) | Clc1cc(ccc1C(=O)Nc1ccc(Cl)c(c1)-c1ccccn1)S(C)(=O)=O | Launched | true | ACH-000970 |
BRD-K46386702-001-02-1 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.698377 | -0.093562 | -0.024701 | 0.878906 | 0.001018 | null | ARRY-334543 | EGFR inhibitor | ERBB2 | null | null | C[C@@H]1COC(Nc2ccc3ncnc(Nc4ccc(OCc5nccs5)c(Cl)c4)c3c2)=N1 | Phase 2 | true | ACH-000970 |
BRD-K49328571-001-15-0 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.582281 | 0.077959 | -0.078461 | 0.739211 | 0.000107 | null | dasatinib | Bcr-Abl kinase inhibitor, ephrin inhibitor, KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, src inhibitor, tyrosine kinase inhibitor | ABL1, ABL2, BLK, EPHA2, FGR, FRK, FYN, HCK, KIT, LCK, LYN, PDGFRB, SRC, SRMS, STAT5B, YES1 | hematologic malignancy | chronic myeloid leukemia (CML), acute lymphoblastic leukemia (ALL) | Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1, Cc1nc(Nc2ncc(s2)C(=O)Nc2c(C)cccc2Cl)cc(n1)N1CCN(CCO)CC1 | Launched | true | ACH-000970 |
BRD-K49350383-001-14-5 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.802922 | 36.374852 | 0.529466 | 1 | 0.559384 | null | thioguanine | purine antagonist | IMPDH1, IMPDH2 | hematologic malignancy | acute myeloid leukemia (AML) | Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1, Nc1nc2nc[nH]c2c(=S)[nH]1 | Launched | true | ACH-000970 |
BRD-K50010139-001-01-5 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.762672 | 0.430734 | 0.150884 | 1 | 9.064935 | null | poziotinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C, COc1cc2ncnc(Nc3ccc(Cl)c(Cl)c3F)c2cc1OC1CCN(CC1)C(=O)C=C | Phase 2 | true | ACH-000970 |
BRD-K50168500-001-07-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.893505 | -1.607681 | 0.031257 | 0.928897 | 0.398889 | null | canertinib | EGFR inhibitor | AKT1, EGFR, ERBB2, ERBB4 | null | null | Fc1ccc(Nc2ncnc3cc(OCCCN4CCOCC4)c(NC(=O)C=C)cc23)cc1Cl | Phase 3 | true | ACH-000970 |
BRD-K51313569-001-07-8 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.304735 | 0.385415 | 0.023729 | 1 | 0.097939 | null | palbociclib | CDK inhibitor | CDK4, CDK6 | oncology | breast cancer | CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O, CC(=O)c1c(C)c2cnc(Nc3ccc(cn3)N3CCNCC3)nc2n(C2CCCC2)c1=O | Launched | true | ACH-000970 |
BRD-K51791723-003-01-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.215037 | 1.210817 | 0.410871 | 0.804702 | 0.935741 | 1.488753 | P276-00 | CDK inhibitor | CDK1, CDK4, CDK9 | null | null | CN1CC[C@H]([C@@H]1CO)c1c(O)cc(O)c2c1oc(cc2=O)-c1ccccc1Cl | Phase 2 | true | ACH-000970 |
BRD-K51967704-001-03-6 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 2.384589 | 0.295758 | 0.241824 | 1 | 3.356201 | null | BIIB021 | HSP inhibitor | HSP90AA1 | null | null | COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C, COc1c(C)cnc(Cn2cnc3c(Cl)nc(N)nc23)c1C | Phase 2 | true | ACH-000970 |
BRD-K52313696-001-12-3 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.394219 | 0.937165 | 0.306473 | 1 | 0.22926 | null | tacedinaline | HDAC inhibitor | HDAC1 | null | null | CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N, CC(=O)Nc1ccc(cc1)C(=O)Nc1ccccc1N | Phase 3 | true | ACH-000970 |
BRD-K53414658-001-08-2 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.979672 | -0.118255 | -0.076095 | 0.988379 | 0.959114 | null | tivozanib | VEGFR inhibitor | FLT1, FLT4, KDR, KIT, PDGFRA, PDGFRB | null | null | COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC | Phase 3 | true | ACH-000970 |
BRD-K53972329-001-07-0 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.895456 | -0.94954 | 0.051581 | 0.981119 | 0.002823 | null | ruxolitinib | JAK inhibitor | JAK1, JAK2, JAK3, TYK2 | hematologic malignancy, hematology | myelofibrosis, polycythemia vera | N#CC[C@H](C1CCCC1)n1cc(cn1)-c1ncnc2[nH]ccc12 | Launched | true | ACH-000970 |
BRD-K54256913-001-08-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.975048 | 0.299991 | -0.024979 | 0.984862 | 0.014452 | null | MK-1775 | WEE1 kinase inhibitor | WEE1 | null | null | CN1CCN(CC1)c1ccc(Nc2ncc3c(n2)n(-c2cccc(n2)C(C)(C)O)n(CC=C)c3=O)cc1 | Phase 2 | true | ACH-000970 |
BRD-K54955827-001-02-2 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.396866 | 3.071141 | 0.047116 | 1 | 0.599185 | null | niraparib | PARP inhibitor | PARP1 | oncology | primary peritoneal cancer (PPC) | NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1, NC(=O)c1cccc2cn(nc12)-c1ccc(cc1)[C@@H]1CCCNC1 | Launched | true | ACH-000970 |
BRD-K54997624-001-06-0 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.766076 | 0.369435 | 0.06915 | 0.849052 | 0.010376 | null | alpelisib | PI3K inhibitor | PIK3CA, PIK3CB, PIK3CD, PIK3CG | null | null | Cc1nc(NC(=O)N2CCC[C@H]2C(N)=O)sc1-c1ccnc(c1)C(C)(C)C(F)(F)F | Phase 3 | true | ACH-000970 |
BRD-K55187425-236-05-2 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.244633 | -4.476304 | -0.028616 | 1 | 0.003854 | null | rigosertib | cell cycle inhibitor, PLK inhibitor | PLK1 | null | null | COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1, COc1cc(OC)c(\C=C\S(=O)(=O)Cc2ccc(OC)c(NCC(O)=O)c2)c(OC)c1 | Phase 3 | true | ACH-000970 |
BRD-K56343971-001-14-8 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.757531 | 2.030757 | 0.151179 | 0.845759 | 0.020835 | null | vemurafenib | RAF inhibitor | BRAF, RAF1 | oncology | melanoma | CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F, CCCS(=O)(=O)Nc1ccc(F)c(C(=O)c2c[nH]c3ncc(cc23)-c2ccc(Cl)cc2)c1F | Launched | true | ACH-000970 |
BRD-K56981171-001-02-8 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.951889 | -0.115473 | -0.258356 | 0.969547 | 9.873672 | null | brigatinib | ALK tyrosine kinase receptor inhibitor, EGFR inhibitor | ALK, EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1, COc1cc(ccc1Nc1ncc(Cl)c(Nc2ccccc2P(C)(C)=O)n1)N1CCC(CC1)N1CCN(C)CC1 | Launched | true | ACH-000970 |
BRD-K57080016-001-15-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.036822 | 0.31181 | 0.920354 | 0.544236 | 0.117396 | 0.150038 | selumetinib | MEK inhibitor | MAP2K1 | null | null | Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO, Cn1cnc2c(F)c(Nc3ccc(Br)cc3Cl)c(cc12)C(=O)NOCCO | Phase 3 | true | ACH-000970 |
BRD-K57169635-001-04-5 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.294183 | -0.282256 | -0.308854 | 1 | 0.568577 | null | dacomitinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | null | null | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1NC(=O)\C=C\CN1CCCCC1 | Phase 3 | true | ACH-000970 |
BRD-K58435339-001-03-0 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 2.231603 | 2.824672 | 0.602649 | 1 | 0.147771 | null | AT13387 | HSP antagonist | HSP90AA1 | null | null | CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O, CC(C)c1cc(C(=O)N2Cc3ccc(CN4CCN(C)CC4)cc3C2)c(O)cc1O | Phase 2 | true | ACH-000970 |
BRD-K58550667-001-08-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.362487 | 2.26358 | 0.429552 | 0.78281 | 0.02291 | 0.040523 | FK-866 | niacinamide phosphoribosyltransferase inhibitor | NAMPT | null | null | O=C(NCCCCC1CCN(CC1)C(=O)c1ccccc1)\C=C\c1cccnc1 | Phase 2 | true | ACH-000970 |
BRD-K59317601-001-05-5 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.92578 | 2.258031 | 0.497162 | 1 | 0.197815 | null | MLN0128 | mTOR inhibitor | MTOR, PIK3CA, PIK3CD, PIK3CG | null | null | CC(C)n1nc(-c2ccc3oc(N)nc3c2)c2c(N)ncnc12 | Phase 2 | true | ACH-000970 |
BRD-K59369769-001-22-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 3.232558 | 0.417449 | 0.048507 | 1 | 9.873693 | null | tozasertib | Aurora kinase inhibitor, Bcr-Abl kinase inhibitor, FLT3 inhibitor, JAK inhibitor | AURKA, AURKB, AURKC, LCK | null | null | CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1, CN1CCN(CC1)c1cc(Nc2cc(C)[nH]n2)nc(Sc2ccc(NC(=O)C3CC3)cc2)n1 | Phase 2 | true | ACH-000970 |
BRD-K60997853-001-02-3 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.426923 | 0.106392 | -0.070625 | 1 | 1,350,433.851946 | null | PHA-848125 | CDK inhibitor, growth factor receptor inhibitor | CDK2, CDK4, CDK7, NTRK1 | null | null | CNC(=O)c1nn(C)c-2c1C(C)(C)Cc1cnc(Nc3ccc(cc3)N3CCN(C)CC3)nc-21 | Phase 2 | true | ACH-000970 |
BRD-K61192372-001-08-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.614706 | -1.424487 | 0.263397 | 0.841612 | 0.032882 | null | capecitabine | DNA synthesis inhibitor, thymidylate synthase inhibitor | TYMS | oncology | breast cancer, colorectal cancer | CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O, CCCCCOC(=O)Nc1nc(=O)n(cc1F)[C@@H]1O[C@H](C)[C@@H](O)[C@H]1O | Launched | true | ACH-000970 |
BRD-K62196610-001-01-6 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.49071 | 0.25169 | 0.020771 | 1 | 0.258724 | null | AVN-944 | inosine monophosphate dehydrogenase inhibitor | IMPDH1, IMPDH2 | null | null | CC[C@H](CC#N)OC(=O)N[C@@H](C)c1cccc(NC(=O)Nc2ccc(-c3cnco3)c(OC)c2)c1 | Phase 2 | true | ACH-000970 |
BRD-K62391742-001-09-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.019278 | 0.896625 | -0.021272 | 1 | 0.048855 | null | venetoclax | BCL inhibitor | BCL2 | hematologic malignancy | chronic lymphocytic leukemia (CLL) | CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1, CC1(C)CCC(CN2CCN(CC2)c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c(c3)[N+]([O-])=O)c(Oc3cnc4[nH]ccc4c3)c2)=C(C1)c1ccc(Cl)cc1 | Launched | true | ACH-000970 |
BRD-K62627508-001-01-5 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 2.293488 | 0.299536 | -0.064611 | 1 | 21.505849 | null | idasanutlin | MDM inhibitor | MDM2, TP53 | null | null | COc1cc(ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@@](C#N)([C@H]1c1cccc(Cl)c1F)c1ccc(Cl)cc1F)C(O)=O | Phase 3 | true | ACH-000970 |
BRD-K63504947-001-14-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.664522 | -0.499528 | 0.041829 | 0.940351 | 0.001185 | null | semaxanib | VEGFR inhibitor | FGFR1, FLT1, KDR, KIT, PDGFRA, PDGFRB, RET | null | null | Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1, Cc1cc(C)c(\C=C2/C(=O)Nc3ccccc23)[nH]1 | Phase 3 | true | ACH-000970 |
BRD-K63712959-001-01-8 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.71262 | 5.903656 | 0.318185 | 0.983676 | 5.800843 | null | temoporfin | radical formation stimulant | null | oncology | head and neck squamous cell carcinoma (HNSCC) | Oc1cccc(c1)-c1c2CCc(n2)c(-c2cccc(O)c2)c2ccc([nH]2)c(-c2cccc(O)c2)c2ccc(n2)c(-c2cccc(O)c2)c2ccc1[nH]2 | Launched | true | ACH-000970 |
BRD-K64052750-001-22-5 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.944055 | -0.159577 | -0.008159 | 0.96541 | 1.856603 | null | gefitinib | EGFR inhibitor | EGFR | oncology | non-small cell lung cancer (NSCLC) | COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN1CCOCC1 | Launched | true | ACH-000970 |
BRD-K66175015-001-12-4 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.904368 | 0.424481 | 0.017236 | 0.952811 | 0.084799 | null | afatinib | EGFR inhibitor | EGFR, ERBB2, ERBB4 | oncology | non-small cell lung cancer (NSCLC) | CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1, CN(C)C\C=C\C(=O)Nc1cc2c(Nc3ccc(F)c(Cl)c3)ncnc2cc1O[C@H]1CCOC1 | Launched | true | ACH-000970 |
BRD-K67844266-003-01-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.606488 | -1.770938 | -0.104565 | 0.955172 | 0.001691 | null | pevonedistat | nedd activating enzyme inhibitor | NAE1, UBA3 | null | null | NS(=O)(=O)OC[C@@H]1C[C@H](C[C@@H]1O)n1ccc2c(N[C@H]3CCc4ccccc34)ncnc12 | Phase 2 | true | ACH-000970 |
BRD-K69001009-001-02-8 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.301466 | 0.27152 | -0.022684 | 1 | 0.484132 | null | golvatinib | VEGFR inhibitor | KDR, MET | null | null | CN1CCN(CC1)C1CCN(CC1)C(=O)Nc1cc(Oc2ccc(NC(=O)C3(CC3)C(=O)Nc3ccc(F)cc3)c(F)c2)ccn1 | Phase 2 | true | ACH-000970 |
BRD-K69694239-001-02-2 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.18623 | -3.543417 | 0.166493 | 1 | 0.558571 | null | bardoxolone-methyl | nuclear factor erythroid derived, like (NRF2) activator | PPARG, STAT3 | null | null | COC(=O)[C@]12CCC(C)(C)C[C@H]1[C@H]1C(=O)C=C3[C@@]4(C)C=C(C#N)C(=O)C(C)(C)[C@@H]4CC[C@@]3(C)[C@]1(C)CC2 | Phase 3 | true | ACH-000970 |
BRD-K69776681-001-03-8 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.608558 | -0.817861 | -0.003028 | 0.991866 | 0.000075 | null | volasertib | PLK inhibitor | PLK1 | null | null | CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O, CC[C@H]1N(C(C)C)c2nc(Nc3ccc(cc3OC)C(=O)N[C@H]3CC[C@@H](CC3)N3CCN(CC4CC4)CC3)ncc2N(C)C1=O | Phase 3 | true | ACH-000970 |
BRD-K70301465-001-05-9 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 2.365848 | -1.490617 | 0.377581 | 1 | 0.00093 | null | ibrutinib | Bruton's tyrosine kinase (BTK) inhibitor | BLK, BMX, BTK | hematologic malignancy | chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), Waldenstrom's macroglobulinemia (WM) | Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C, Nc1ncnc2n(nc(-c3ccc(Oc4ccccc4)cc3)c12)[C@@H]1CCCN(C1)C(=O)C=C | Launched | true | ACH-000970 |
BRD-K70401845-001-15-7 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.124424 | 0.949576 | 0.005901 | 1 | 60.059739 | null | erlotinib | EGFR inhibitor | EGFR, NR1I2 | oncology | non-small cell lung cancer (NSCLC), pancreatic cancer | COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC, COCCOc1cc2ncnc(Nc3cccc(c3)C#C)c2cc1OCCOC | Launched | true | ACH-000970 |
BRD-K73838513-003-05-5 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.510956 | 0.27045 | 0.08883 | 0.786047 | 0.225056 | null | cinacalcet | calcium channel activator | CASR | endocrinology, nephrology, oncology | hyperparathyroidism, chronic kidney disease (CKD), parathyroid carcinoma, hypercalcemia | C[C@@H](NCCCc1cccc(c1)C(F)(F)F)c1cccc2ccccc12 | Launched | true | ACH-000970 |
BRD-K74514084-003-09-2 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.911071 | 1.283927 | -0.078316 | 0.988473 | 3.378139 | null | pazopanib | KIT inhibitor, PDGFR tyrosine kinase receptor inhibitor, VEGFR inhibitor | CSF1R, FGF1, FGFR1, FGFR3, FLT1, FLT4, ITK, KDR, KIT, PDGFRA, PDGFRB, SH2B3 | oncology | renal cell carcinoma (RCC), soft tissue sarcoma (STS) | CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1, CN(c1ccc2c(C)n(C)nc2c1)c1ccnc(Nc2ccc(C)c(c2)S(N)(=O)=O)n1 | Launched | true | ACH-000970 |
BRD-K75009076-001-02-1 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 0.08325 | 1.718132 | 0.426914 | 0.894563 | 3.592828 | 3.994583 | SCH-900776 | CHK inhibitor | CDK2, CHEK1 | null | null | Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1, Cn1cc(cn1)-c1cnn2c(N)c(Br)c(nc12)[C@@H]1CCCNC1 | Phase 2 | true | ACH-000970 |
BRD-K76210423-001-01-6 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.158112 | -0.144107 | -0.001522 | 1 | 0.029709 | null | resiquimod | toll-like receptor agonist | TLR7, TLR8 | null | null | CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O | Phase 3 | true | ACH-000970 |
BRD-K76239644-001-02-6 | ACH-000970 | SNUC5_LARGE_INTESTINE | MTS010 | 1 | 1.123555 | -0.023353 | -0.047403 | 1 | 71,990,265.191409 | null | BMS-690514 | EGFR inhibitor, VEGFR inhibitor | EGFR, ERBB2, FLT3, KDR | null | null | COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1, COc1cccc(Nc2ncnn3ccc(CN4CC[C@@H](N)[C@H](O)C4)c23)c1 | Phase 2 | true | ACH-000970 |
Subsets and Splits
No saved queries yet
Save your SQL queries to embed, download, and access them later. Queries will appear here once saved.